Table 1.

Classification of hepcidin agonists

Hepcidin agonists	Company	Drug	Target	Clinical trials	Reference
Class 1: hepcidin mimetics	University of California, Los Angeles	MHs (PR65, PR73, M009, M012)	Ferroportin	Validated in preclinical studies	See articles cited in the review
	La Jolla Pharmaceutical Company	LJPC-401 (hepcidin formulation)	Ferroportin	Phase 1: no toxicity reported; expected hypoferremia observed	45
	Protagonist Therapeutics	PTG-300	Ferroportin	Phase 1: no serious adverse events reported; expected hypoferremia observed	58
Class 2: stimulators of hepcidin production	Ionis Pharmaceuticals	Tmprss6-ASO	Tmprss6	Phase 1 ongoing	59
	Alnylam Pharmaceuticals	Tmprss6-siRNA	Tmprss6	Validated in preclinical studies	See articles cited in the review
Class 3: ferroportin inhibitors	Vifor Pharma	VIT-2763	Ferroportin	Phase 1 planned in 2018	60

ASO, antisense oligonucleotide; siRNA, small-interfering RNA.